The thesis that started it all
Before we ever met Avnish Chhabria, we had spent months building a conviction on one of India's most overlooked consumer categories: Nutraceuticals. The opportunity was enormous and hiding in plain sight. India's nutraceutical market was valued at $5.2 billion in 2019, growing at a CAGR of 17.5% — nearly double the global growth rate of 8.2% — and was expected to reach $10 billion by 2023.
Globally, the market stood at $123 billion, with Asia Pacific already commanding close to 30% of total revenue share. Yet India was dramatically underpenetrated relative to its population and its health burden — a country where over 80% of the population is protein deficient, where three in four people are deficient in at least one critical vitamin, and where the dominant market response was a shelf full of tablets and capsules that consumers neither trusted nor wanted to take.
Our thesis identified three structural problems with the existing landscape — and three corresponding opportunities that a new generation of brands could seize. This was further reinforced by the Covid tailwind-led desire for immunity products, as consumers moved from a “curative” mindset to a “preventive” one.
The first problem was product quality and trust. The market was flooded with low-quality products of questionable efficacy. Leading incumbents held significant distribution power but had built their portfolios around commodity formulations, generic one-size-fits-all products, and a pharmaceutical positioning that left consumers without guidance, education, or meaningful outcomes.
The second was form factor inertia. A deep-rooted cultural aversion to taking tablets and capsules, unless prescribed by a doctor, was suppressing category penetration, particularly among younger urban consumers. Traditional pill formats simply didn't fit a modern, busy lifestyle. The global shift toward gummies, effervescents, soft-gels, and dissolvable oral strips had barely touched India, and the brands best positioned to lead that shift hadn't yet emerged.
The third was a white space in high-growth categories. General wellness, digestive health, and cardiometabolic supplements were saturated with Rx-driven, commoditised products. But segments like beauty-from-within, skin and hair nutrition, cognition and mental health, sleep, sports performance, and gender-specific wellness were small, underpenetrated, and under-innovated. Online channels were projected to grow from INR 1,500 Cr in 2019 to INR 7,000 Cr by 2025, and the brands that would win in these emerging segments promised to be disproportionate winners.
Our thesis, in short, was this: A new kind of nutraceutical brand — one built on science-backed formulations, clinically studied ingredients, innovative delivery formats, and a digital-first D2C model — had the potential to build a large, high-margin consumer business in India. The brand that could own these attributes authentically, across a wide range of functional areas, while maintaining the capital discipline to grow sustainably, would be very hard to displace.
In 2021, we set out to look for that brand. We found it in Wellbeing Nutrition.
Great products, a seasoned founder, and a thesis fit
When we first evaluated Wellbeing Nutrition in early 2021, the company had a deceptively modest footprint, with just two products (GrandMa’s Kadha and Daily Greens) on offer. But three things set it apart from the dozens of nutraceutical brands we had evaluated.
First, product innovation. Avnish had spent nearly three years obsessing over ingredient sourcing, formulation science, and form factors before scaling distribution. Every product, from the Daily Greens effervescent to the Grandma's Kadha immunity tablet, was manufactured in a US FDA-approved facility, certified USDA Organic, and developed using clinically studied ingredients. This wasn't a marketing claim. It was embedded in the supply chain. In our competitive benchmarking across investable nutraceutical opportunities, Wellbeing scored a 9 out of 10 on product rating — the highest in our cohort.
Second, the founder. In our quantitative assessment of the investable landscape, Avnish scored the strongest among all brands we evaluated. A serial entrepreneur, with experience across operating and consulting businesses, he had a rare combination of financial rigour, brand intuition, and product obsession.
Third, the fit to our thesis was near-perfect. Wellbeing's product architecture featured oral melts, effervescent tablets, slow-release capsules, and the like – addressing the form factor problem head-on. Its positioning in emerging, underpenetrated high-growth categories like gut health, sleep, collagen, and sports nutrition aligned precisely with the white spaces we had identified. And its digital-first, D2C model was built for exactly the channel shift we had anticipated.
Building deliberately
The months following our initial investment were not without turbulence. Like most D2C brands in 2021-22, Wellbeing faced the dual pressure of high-performance marketing costs and heavy discounting by competitors.
But the response was instructive. Rather than chase growth at the expense of margins, Avnish made a series of deliberate decisions. With our help, he brought on the ex-digital marketing agency co-founder, Saurabh Kapoor, as a co-founder & CBO to build the online business, and accelerate growth. The pricing strategy was rejigged, which in turn unlocked significant growth and the product portfolio grew from 4 SKUs to over 30 SKUs, covering 19 functional areas. The Wellbeing offline footprint grew from a handful of stores to over 1,000.
The results were hard to argue with. In a year’s time, Wellbeing had grown 4.4x, and its ARR crossed INR 50 Cr, with a capital efficiency ratio of ~3x.
The brand also made smart use of equity-light celebrity partnerships by onboarding Rakulpreet Singh, Mira Kapoor, and Dulquer Salmaan as brand equity partners, as well as secured a landmark global collaboration with Disney and Marvel for a USDA Organic-certified kids' nutrition range, the first of its kind in the world.
A new chapter with HUL
By late 2022, the business had drawn the attention of Hindustan Unilever (HUL), one of India's most sophisticated FMCG operators. They led the next funding round, taking a significant minority stake, and providing Wellbeing with, both, a strategic partner with deep distribution reach, as well as an institutional validator. We at Fireside also participated in the funding round to preserve our holding in the business showcasing our reinforced conviction in the business.
The scale-up
The brand architecture was defined, and the product strategy was streamlined in-line, focused on building leadership in the “beauty from within,” as well as the sports and performance segments. Further, on the organization front, the entire leadership team was built out, including the CFO, whom we helped onboard.
What happened next was a disciplined, multi-front expansion that played out almost exactly along the lines of our original thesis. Wellbeing's product architecture evolved into three core pillars: Sports and Performance (47% of sales, anchored by whey protein isolates, creatine, and vegan protein), Daily Essentials (28% of sales, led by the SLOW magnesium range, and sleep and stress supplements), Beauty and HSN (19% of sales, with marine collagen and skin glow products).
Channel diversification matured significantly. E-commerce platforms led sales, followed by the brand's own website, offline modern trade and pharmacies, and quick commerce. Average order value had risen to INR 1,900, and retention metrics, which are a critical indicator of product efficacy in this category, improved to 45% with strengthening cohort behaviour.
The supply chain remained a source of genuine competitive advantage. Full control over procurement, US FDA-registered third-party manufacturing, and multi-layered quality checks from sourcing to production meant Wellbeing could scale rapidly without compromising quality. It became one of the few Clean Label Project-certified protein brands globally, a distinction that opened international expansion avenues as well.
Strong focus on building a sustainable business backed by robust unit economics helped shape the overall business and the P&L for the brand. By the end of last year, Wellbeing had reached an ARR of INR 250 Cr with gross margins of 60% and a robust capital efficiency of ~3x across its full investment lifecycle.
Finding Wellbeing its best possible home
As investors, exits are something we think about from the day we write the first cheque. But not all exits are created equal. A great exit isn't simply a financial event: It's about finding the right home for a brand you've spent years building alongside a founder, a team, and a consumer community that trusts it. With USV, we believe we found exactly that.
USV is not a passive acquirer. A leading Indian multinational pharmaceutical and biotechnology company founded in 1961, with deep specialisation in diabetes, cardiology, and biosimilars, USV brings something genuinely rare to a brand like Wellbeing: scientific credibility, national distribution infrastructure, regulatory expertise, and the institutional depth to take a science-backed nutrition brand to its next order of magnitude. For a brand whose entire identity is built on clinically validated ingredients, rigorous manufacturing, and efficacy-first positioning, a home within a large and credible pharmaceutical organisation is more than just a happy financial outcome. It is a natural and strategic fit.
While USV now holds significant majority in the company, the balance remains with the founder and the ESOP pool. Avnish stays. The team stays. The mission stays. What changes is the scale of the platform from which Wellbeing can now pursue it: New geographies. New channels. New categories. And a pharma-grade supply chain that can underpin global ambitions.
For Fireside, this was a full exit that delivered strong returns. But what gives us the most satisfaction isn't the valuation alone. It’s knowing that a brand we believed in from its earliest days, when it had two products and ~INR 80 lakh in monthly net revenue, will now continue to grow, deepen its consumer relationships, and fulfil its mission of making science-backed nutrition accessible to every Indian household.
